Menopausal hormones and breast cancer in a biracial population

American Journal of Public Health

Volumn 90, Issue 6, 2000, Pages 966-971

  Moorman, Patricia G ^a   Kuwabara, Hiroyo ^a   Millikan, Robert C ^b   Newman, Beth ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; RACE DIFFERENCE; RISK ASSESSMENT;

EID: 0034120164     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.90.6.966     Document Type: Article

References (31)

1. Speroff L. Postmenopausal hormone therapy and the risk of breast cancer. Maturitas. 1999; 32:123-129.
2. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985-1990.
3. Sillero-Arenas M, Delgado-Rodriquez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol. 1992;79:286-294.
4. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993;168:1473-1480.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997; 350:1047-1059.
6. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among White, Hispanic, and Black women in the United States. J Natl Cancer Inst. 1994;86:705-712.
7. Millikan RC, Pittman GS, Tse C-KJ, et al. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis. 1998;19:1943-1947.
8. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 1998;58:5038-5041.
9. Hutchinson RG, Watson RL, Davis CE, et al., for the ARIC Study Group. Racial differences in risk factors for atherosclerosis. Angiology. 1997;48:279-290.
10. Newman B, Moorman PG, Millikan R, et al. The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat. 1995;35:51-60.
11. Aldrich TE, Vann D, Moorman PG, Newman B. Rapid reporting of cancer incidence in a population-based study of breast cancer: one constructive use of a central cancer registry. Breast Cancer Res Treat. 1995;35:61-64.
12. Weinberg CR, Sandler DP. Randomized recruitment in case-control studies. Am J Epidemiol. 1991;134:421-432.
13. Moorman PG, Newman B, Millikan RC, Tse C-KJ, Sandler DP. Participation rates in a case-control study: the impact of age, race, and race of interviewer. Ann Epidemiol. 1999;9:188-195.
14. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol. 1997;145:536-545.
15. Rosenberg L, Palmer JR, Rao RS, Adams-Campbell LL. Correlates of postmenopausal female hormone use among black women in the United States. Obstet Gynecol. 1998;91: 454-458.
16. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
17. Folsom AR, Mink PJ, Sellers TA, Hong C-P, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995;85:1128-1132.
18. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. 1995;142:788-795.
19. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995;274:137-142.
20. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control. 1994;5:491-500.
21. Barrett-Connor E. Postmenopausal estrogen and the risk of breast cancer. Ann Epidemiol. 1994;4:177-180.
22. Pham K-TC, Grisso JA, Freeman EW. Ovarian aging and hormone replacement therapy. J Gen Intern Med. 1997;12:230-236.
23. Holmes-Rovner M, Padonu G, Kroll J, et al. African-American women's attitudes and expectations of menopause. Am J Prev Med. 1996;12:420-423.
24. Rousseau ME, McCool WF. The menopausal experience of African American women: overview and suggestions for research. Health Care Women Int. 1997;18:233-250.
25. Smith RA, Haynes S. Barriers to screening for breast cancer. Cancer. 1992;69:1968-1978.
26. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;277:1140-1147.
27. Smith HO, Kammerer-Doak DN, Barbo DM, Sarto GE. Hormone replacement therapy in the menopause: a pro opinion. CA Cancer J Clin. 1996;46:343-363.
28. Lip GY, Beevers G, Zarifis J. Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint. J Intern Med. 1995;238:389-399.
29. Lobo RA. Benefits and risk of estrogen replacement therapy. Am J Obstet Gynecol. 1995;173: 982-990.
30. Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet Gynecol. 1990;75:77S-80S.
31. Samsioe G. Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil Menopausal Stud. 1996;41:11-15.